Recent announcements

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
2022
November
Press Release
29 Nov
2022

POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model. 177Lu-PNT6555, the lead of the PNT2004 pan-cancer fibroblast activation protein-α (FAP-α) targeted program, is currently in a phase 1 trial.

2022
November
Press Release
14 Nov
2022

POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. (NASDAQ: LNTH) for the commercialization of PNT2002 & PNT2003.

2022
November
Press Release
14 Nov
2022

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

Upon consummation of the agreements, in exchange for the exclusive worldwide rights[1], Lantheus will pay a total of $260 million in upfront payments between the two agreements to POINT, with the potential for additional milestone payments of approximately $1.8 billion between the two products based on U.S. Food and Drug Administration (FDA) approval and net sales and commercial milestones. Additionally, Lantheus will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003. Additional terms of the agreements are summarized below and a website with more information about the collaboration is accessible at www.strategiccollaboration.net

2022
October
Press Release
17 Oct
2022

POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress

PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225. Targeting IND/CTA submission for PNT2001 program in H1 2023.

2022
September
Press Release
16 Sep
2022

POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock

Today the Company announced the closing of its previously announced underwritten public offering of 13,900,000 shares of Common Stock at a public offering price of $9.00 per share. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $125 million.

2022
September
Press Release
13 Sep
2022

POINT Biopharma Announces Proposed Public Offering of Common Stock

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that it has commenced an underwritten public offering of its common stock.

2022
September
Press Release
10 Sep
2022

POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022

Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: a median rPFS time of 11.5 months, a best radiographic objective response (CR, PR) was achieved in 60% of the 10 participants with evaluable disease at baseline, and PNT2002 was well tolerated with no treatment-related deaths.

2022
September
Press Release
4 Sep
2022

POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

An abstract is now available on the ESMO congress website at https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal_2/presentation/list?q=1400P, and an e-poster which contains updated data will be published and presented on Sunday, September 11th.